Atorvastatin enhances the plasma clearance of chylomicron-like emulsions in subjects with atherogenic dyslipidemia: Relevance to the in vivo metabolism of triglyceride-rich lipoproteins

Atherosclerosis

Volumn 166, Issue 2, 2003, Pages 311-321

  Sposito, Andrei C ^a,b   Santos, Raul D ^a   Amâncio, Rosangela F ^a   Ramires, Jose A F ^a   Chapman, M John ^b   Maranhão, Raul C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Chylomicrons; HMG CoA reductase inhibitor; Remnants; Triglyceride

Indexed keywords

ATORVASTATIN; CHOLESTEROL OLEATE; CHYLOMICRON; FATTY ACID DERIVATIVE; LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL; TRIOLEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CALCULATION; CATABOLISM; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DRUG EFFECT; DYSLIPIDEMIA; EMULSION; FEMALE; HUMAN; IN VIVO STUDY; KINETICS; MAJOR CLINICAL STUDY; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN METABOLISM;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHYLOMICRONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FAT EMULSIONS, INTRAVENOUS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PARTICLE SIZE; PROBABILITY; PYRROLES; TRIGLYCERIDES;

EID: 0037298362     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00334-9     Document Type: Article

References (44)

1. Groot P.H., Van Stiphout W.A.H.J., Krauss X.H., Jansen H., Van Tol A., Van Ramshorst E., et al. Post-prandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler. Thromb. 11:1991;653-662.
2. Patsch J.R., Miesenbock G., Hopferwieser T., Muhlberger V., Knapp E., Dunn J.K. Gotto relation of triglyceride metabolism and coronary artery disease: studies in post-prandial state. Arterioscler. Thromb. 2:1992;1336-1345.
3. Weintraub M.S., Grosskopf I., Rassin T., Miller H., Charach G., Rotmensch H.H., et al. Clearance of chylomicron remnants in normolipidemic patients with coronary artery disease: case control study over 3 years. Br. Med. J. 312:1996;935-939.
4. Maranhao R.C., Feres M.C., Martins M.T., Mesquita C.H., Toffoletto O., Vinagre C.G., et al. Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease. Atherosclerosis. 126:1996;15-25.
5. Van Lenten B.J., Fogelman A.M., Jackson R.L., Shapiro S., Haberland M.E., Edwards P.A. Receptor-mediated uptake of remnant lipoproteins by cholesterol-loaded human monocyte-macrophages. J. Biol. Chem. 260:1985;8783-8788.
6. Hussain M., Kancha R.K., Zhou Z., Luchoomun J., Zu H., Bakillah A. Chylomicron assembly and catabolism: role of apolipoproteins and receptors. Biochim. Biophys. Acta. 1300:1996;151-170.
7. Lassel T.S., Guerin M., Auboiron S., Chapman M.J., Guy-Grand B. Preferential cholesteryl ester acceptors among triglyceride-rich lipoproteins during alimentary lipemia in normolipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 18:1998;65-74.
8. Nakandakare E.R., Lottenberg S.A., Oliveira H.C.F., Bertolami M.C., Vasconcelos K.S., Sperotto G., et al. Simultaneous measurements of chylomicron and remnant removal using a doubly labelled artificial lipid emulsion: studies in normolipidemic and hyperlipidemic subjects. J. Lipid Res. 35:1994;143-152.
9. Sposito A.C., Maranhao R.C., Vinagre C.G., Santos R.D., Ramires J.A. Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease. Atherosclerosis. 154:2001;455-461.
10. Santos R.D., Ventura L.I., Sposito A.C., Schreiber R., Ramires J.Á., Maranhao R.C. The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia. Cardiovasc. Res. 49:2001;456-465.
11. Knopp R.H. Drug treatment of lipid disorders. N. Engl. J. Med. 341:1999;498-511.
12. Cianflone K., Bilodeau M., Davingnon J., Sniderman A.D. Modulation of chylomicron remnant metabolism by a hepatic hydroxymethylgluratyl coenzyme A reductase inhibitor. Metabolism. 39:1990;274-280.
13. Castro Cabezas M., de Bruin T.W.A., Kock L.A.W., Kortlandt W., Trip M.V.L.S., Jansen H., et al. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. Metabolism. 42:1993;497-503.
14. Santos R.D., Sposito A.C., Ventura L.I., Cesar L.A., Ramires J.A., Maranhao R.C. Effect of pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease. Am. J. Cardiol. 85:2000;1163-1166.
15. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. 81:1998;582-587.
16. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J., Davignon J., Isaacsohn J.L., Weiss S.R., et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J. Am. Med. Assoc. 275:1996;128-133.
17. Burnett J.R., Barrett P.H., Vicini P., Miller D.B., Telford D.E., Kleinstiver S.J., et al. The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. Arterioscler. Thromb. Vasc. Biol. 18:1998;1906-1914.
18. Parhofer K.G., Barrett P.H., Schwandt P. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemic subjects. J. Clin. Endocrinol. Metab. 85:2000;4224-4230.
19. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31:1990;545-548.
20. Redgrave T.G., Zech L.A. A kinetic model of chylomicron core lipid metabolism in rats: the effect of a single meal. J. Lipid Res. 5:1987;473-482.
21. Redgrave T.G., Ly H.L., Quintao E.C., Ramberg C.F., Boston R.C. Clearance from plasma of triacylglycerol and cholesteryl ester after intravenous injection of chylomicron-like lipid emulsions in rats and man. Biochem. J. 290:1993;843-847.
22. Redgrave T.G., Maranhão R.C. Metabolism of protein-free emulsion models of chylomicrons in rats. Biochim. Biophys. Acta. 835:1985;104-112.
23. 137C transfer rates in marine organisms and dose in man. J. Radioan. Nucl. Chem. 232:1998;233-236.
24. Redgrave T.G., Maranhao R.C., Tercyak A.M., Lincoln E.C., Brunengraber H. Uptake of artificial model remnant lipoprotein emulsions by the perfused rat liver. Lipids. 23:1988;101-105.
25. Borba E.F., Bonfa E., Vinagre C.G., Ramires J.A., Maranhao R.C. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum. 43:2000;1033-1040.
26. Vinagre C.G., Stolf N.A., Bocchi E., Maranhao R.C. Chylomicron metabolism in patients submitted to cardiac transplantation. Transplantation. 69:2000;532-537.
27. Berr F., Kern F. Jr. Plasma clearance of chylomicrons labeled with retinyl-palmiatate in healthy human subjects. J. Lipid Res. 25:1984;805-812.
28. Cortner J.A., Coates P.M., Le N.A., Cryer D.R., Ragni M.C., Faulkner A., et al. Kinetics of chylomicron remnant clearance in normal and in hyperlipoproteinemic subjects. J. Lipid Res. 28:1987;195-206.
29. Grundy S.M., Mok H.Y.I. Chylomicron clearance in normal and hyperlipidemic men. Metabolism. 25:1976;1225-1239.
30. Cohen J.C. Chylomicron triglyceride clearance: comparison of three assessment methods. Am. J. Clin. Nutr. 49:1989;306-313.
31. Ginsberg H.N., Huang L.S. Atherogenic dislipidemia. J. Cardiovasc. Risk. 7:2000;325-331.
32. Karpe F. Mechanisms of postprandial hyperlipidaemia - remnants and coronary artery disease. Diabet. Med. 3:(14 Suppl.):1997;S60-S66.
33. Hultin M., Savonen R., Olivecrona T. Chylomicron metabolism in rats: lipolysis, recirculation of triglyceride derived fatty acids in plasma FFA, and fate of core lipids as analyzed by compartmental modeling. J. Lipid Res. 37:1996;1022-1036.
34. Vega G.L., Grundy S.M. Effect of statins on metabolism of Apo B-containing lipoproteins in hypertriglyceridemic men. Am. J. Cardiol. 81:(4A):1998;36B-42B.
35. Cooper A.D. Hepatic uptake of chylomicron remnants. J. Lipid Res. 38:1997;2173-2192.
36. Cabezas M.C., de Bruin T.W., Westerfeld H.E., Meijer E., Erkelens D.W. Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolemia. J. Intern. Med. 244:1998;299-300.
37. Rubinstzein D.C., Cohen J.C., Berger G.M., van der Westhuyzien D.R., Coetzee G.A., Givers W. Chylomicron remnant clearance from plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J. Clin. Invest. 86:1990;1306-1312.
38. Mamo J.C., Smith D., Yu K.C., Kawaguchi A., Harada-Shiba M., yamamura T., et al. Accumulation of chylomicron remnants in homozygous subjects with familial hypercholesterolemia. Eur. J. Clin. Invest. 28:1998;379-384.
39. Alaupovic P., Heinonen T., Schurzinske L., Black D. Effect of new HMGCo-A reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. Atherosclerosis. 133:1997;123-133.
40. Dixon J.L., Ginsberg H.N. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J. Lipid Res. 34:1993;167-179.
41. Isusi E., Aspichueta P., Liza M., Hernandez M.L., Diaz C., Hernandez G., et al. Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes. Atherosclerosis. 153:2000;283-294.
42. Burnett J.R., Wilcox L.J., Telford D.E., Kleinstiver S.J., Barret P.H.R., Newton R.S., et al. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hidroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs. Endocrinology. 140:1999;5293-5302.
43. Hasty A.H., Linton M.F., Swift L.L., Fazio S. Determination of the lower threshold of apolipoprotein E resulting in remnant lipoprotein clearance. J. Lipid Res. 40:1999;1529-1538.
44. Walden C.C., Hegele R.A. Apolipoprotein E in hyperlipidemia. Ann. Intern. Med. 120:1994;1026-1036.